Meghan Lovegren

1.3k total citations · 2 hit papers
25 papers, 894 citations indexed

About

Meghan Lovegren is a scholar working on Psychiatry and Mental health, Neurology and Sensory Systems. According to data from OpenAlex, Meghan Lovegren has authored 25 papers receiving a total of 894 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 8 papers in Neurology and 7 papers in Sensory Systems. Recurrent topics in Meghan Lovegren's work include Migraine and Headache Studies (19 papers), Olfactory and Sensory Function Studies (7 papers) and Botulinum Toxin and Related Neurological Disorders (6 papers). Meghan Lovegren is often cited by papers focused on Migraine and Headache Studies (19 papers), Olfactory and Sensory Function Studies (7 papers) and Botulinum Toxin and Related Neurological Disorders (6 papers). Meghan Lovegren collaborates with scholars based in United States, Canada and Australia. Meghan Lovegren's co-authors include Paul Sabbatini, Robert G. Maki, William P. Tong, Ennapadam Venkatraman, David R. Spriggs, Richard R. Barakat, Carol Aghajanian, Martee L. Hensley, Robert Croop and Richard B. Lipton and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Neurology.

In The Last Decade

Meghan Lovegren

21 papers receiving 875 citations

Hit Papers

Gemcitabine and Docetaxel in Patients With Unresectable L... 2002 2026 2010 2018 2002 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
    2002 498 citations Martee L. Hensley, Robert G. Maki et al. Journal of Clinical Oncology profile →
  2. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
    2023 85 citations Richard B. Lipton, Robert Croop et al. The Lancet Neurology profile →

Peers

Meghan Lovegren
Comparison fields: 5 of 68
  • Pulmonary and Respiratory Medicine 414
  • Oncology 260
  • Psychiatry and Mental health 251
  • Pathology and Forensic Medicine 219
  • Cardiology and Cardiovascular Medicine 136
Replace Wakoh Takahashi with:
Wakoh Takahashi Japan
Georg Wiltberger Germany
Benjamin Lyons United States
Janci L. Chunn United States
Giulia Turri Italy
Shung‐Shung Sun Taiwan
Yuebing Li United States
Rory R. Dalton United States
Toshihiro Yasui Japan
Bárbara Juarez Amorim Brazil
Wakoh Takahashi Japan View profile →
Citations per field, relative to Meghan Lovegren
Meghan Lovegren · 1×
Citations per year, relative to Meghan Lovegren
Meghan Lovegren · 1×

Countries citing papers authored by Meghan Lovegren

Since Specialization
Citations

This map shows the geographic impact of Meghan Lovegren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meghan Lovegren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meghan Lovegren more than expected).

Fields of papers citing papers by Meghan Lovegren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meghan Lovegren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meghan Lovegren. The network helps show where Meghan Lovegren may publish in the future.

Co-authorship network of co-authors of Meghan Lovegren

This figure shows the co-authorship network connecting the top 25 collaborators of Meghan Lovegren. A scholar is included among the top collaborators of Meghan Lovegren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meghan Lovegren. Meghan Lovegren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine
2024 ·Cephalalgia ·Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry, Meghan Lovegren, Gilbert L’Italien, Richard B. Lipton
22
2
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial breakdown →
2023 ·The Lancet Neurology ·Richard B. Lipton, Robert Croop, David Stock, Jennifer Madonia, Micaela Forshaw, Meghan Lovegren, (unknown), Vladimir Coric, Peter J. Goadsby
85
3
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine (P9-12.002)
2023 ·Neurology ·Robert Croop, Jennifer Madonia, (unknown), (unknown), Meghan Lovegren, Richard Lipton
2
4
Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials (P9-12.003)
2023 ·Neurology ·(unknown), Timothy W. Smith, Jelena Pavlović, Kathleen Mullin, Robert Croop, Jennifer Madonia, (unknown), Meghan Lovegren, Micaela Forshaw, Richard B. Lipton
0
5
Zavegepant 10 mg Nasal Spray is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials (S47.003)
2023 ·Neurology ·Jelena Pavlović, Timothy R. Smith, Kathleen Mullin, (unknown), Robert Croop, Jennifer Madonia, (unknown), Meghan Lovegren, Micaela Forshaw, Richard Lipton
0
6
Zavegepant Nasal Spray for the Acute Treatment of Migraine With Aura and Without Aura: Pooled Results From 2 Randomized, Placebo-Controlled Clinical Trials (S47.004)
2023 ·Neurology ·Timothy W. Smith, Jelena Pavlović, Kathleen Mullin, (unknown), Robert Croop, Jennifer Madonia, (unknown), Meghan Lovegren, Micaela Forshaw, Richard B. Lipton
0
7
Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study (2370)
2021 ·Neurology ·Jack Schim, Susan Hutchinson, Richard B. Lipton, Robert Croop, Elyse Stock, Alexandra Thiry, Charles M. Conway, Meghan Lovegren, Vlad Coric, (unknown)
4
8
Long-term Use of Rimegepant 75 mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics (5072)
2021 ·Neurology ·David Kudrow, Kathleen Mullin, Gary Berman, Richard B. Lipton, (unknown), Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop
2
9
Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults With a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study (5084)
2021 ·Neurology ·Ira Turner, Jelena Pavlović, Richard B. Lipton, (unknown), Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop
1
10
Acute Treatment of Migraine with Rimegepant Improves Health Related Quality of Life in Adults With a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study (5029)
2021 ·Neurology ·Ira Turner, Paul Winner, Richard B. Lipton, (unknown), Gilbert L’Italien, Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop
1
11
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study (1995)
2021 ·Neurology ·Susan Hutchinson, Jack Schim, Richard B. Lipton, Robert Croop, (unknown), Alexandra Thiry, Elyse Stock, Charles M. Conway, Meghan Lovegren, Vlad Coric, Michael G. Hanna
7
12
Rimegepant 75 mg for the Acute Treatment of Migraine in Adults With Frequent Migraine: Long-Term Safety and Clinical Improvement Versus Baseline (5054)
2021 ·Neurology ·Kathleen Mullin, Susan Hutchinson, Timothy R. Smith, Richard B. Lipton, (unknown), (unknown), Alexandra Thiry, Meghan Lovegren, Charles M. Conway, Vlad Coric, Robert Croop
3
13
Acute Treatment of Migraine with Oral Rimegepant 75 mg Confers Robust Improvement in Absenteeism, Presenteeism and Productivity: Results from a One Year, Open-Label, Safety Study (BHV3000-201) (1864)
2020 ·Neurology ·Gilbert L’Italien, Robert Croop, Elyse Stock, Alexandra Thiry, (unknown), Meghan Lovegren, (unknown), Vladimir Coric, Richard B. Lipton
1
14
Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201) (4829)
2020 ·Neurology ·Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Elyse Stock, Alexandra Thiry, Charles M. Conway, (unknown), Meghan Lovegren, Vladimir Coric, Richard B. Lipton
10
15
Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112)
2020 ·Neurology ·(unknown), Robert Croop, Richard B. Lipton, Elyse Stock, Alexandra Thiry, Charles M. Conway, Meghan Lovegren, Vladimir Coric, Gilbert L’Italien
0
16
Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201) (1943)
2020 ·Neurology ·Linda Harris, Gilbert L’Italien, Robert Croop, Elyse Stock, Alexandra Thiry, (unknown), Meghan Lovegren, (unknown), Vladimir Coric, Richard Lipton
1
17
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
2020 ·Headache The Journal of Head and Face Pain ·Gary Berman, Robert Croop, David Kudrow, (unknown), Meghan Lovegren, Alexandra Thiry, Charles M. Conway, Vladimir Coric, Richard B. Lipton
71
18
Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B
2012 ·Gastroenterology ·Anna S. Lok, (unknown), Giampiero Carosi, Ulus Salih Akarca, Adrián Gadano, François Habersetzer, William Sievert, David Wong, Meghan Lovegren, David J. Cohen, Cyril Llamoso
111
19
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?
2006 ·International Journal of Gynecological Cancer ·Jakob Dupont, Carol Aghajanian, (unknown), Meghan Lovegren, Shaokun Chuai, E. S. Venkatraman, Martee L. Hensley, Sibyl Anderson, David R. Spriggs, Paul Sabbatini
6
20
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial breakdown →
2002 ·Journal of Clinical Oncology ·Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman, (unknown), Meghan Lovegren, Carol Aghajanian, Paul Sabbatini, William P. Tong, Richard R. Barakat, David R. Spriggs
498

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wakoh Takahashi Breakdown of academic impact, for papers by Georg Wiltberger Breakdown of academic impact, for papers by Benjamin Lyons Breakdown of academic impact, for papers by Janci L. Chunn Breakdown of academic impact, for papers by Giulia Turri Breakdown of academic impact, for papers by Shung‐Shung Sun Breakdown of academic impact, for papers by Yuebing Li Breakdown of academic impact, for papers by Rory R. Dalton Breakdown of academic impact, for papers by Toshihiro Yasui Breakdown of academic impact, for papers by Bárbara Juarez Amorim
Rankless by CCL
2026